Senior Management Led | Transactions

Has Completed an Option Deal and Financing Led By

IRX Therapeutics: a clinical-stage company developing novel immunotherapies

IRX Therapeutics is a clinical-stage company developing novel immunotherapies focused on reducing the immune suppression that is seen in the cancer tumor micro-environment, restoring immune function, and activating a coordinated immune response against the tumor. The lead candidate, IRX-2, is a proprietary therapeutic containing numerous active cytokine components. Data collected to date indicates that IRX-2 acts to restore and activate multiple immune cell types, including T cells, dendritic cells, and natural killer cells, to recognize and destroy tumors. For more information about the Company and its clinical programs, please visit www.IRXTherapeutics.com.